Evoke Pharma (EVOK) Expected to Announce Quarterly Earnings on Tuesday

Evoke Pharma (NASDAQ:EVOK) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $3.32 million for the quarter.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.24). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The business had revenue of $3.31 million for the quarter, compared to analysts’ expectations of $3.08 million.

Evoke Pharma Price Performance

Shares of Evoke Pharma stock opened at $3.14 on Monday. The firm has a fifty day moving average price of $2.83 and a 200 day moving average price of $4.09. Evoke Pharma has a 1 year low of $1.94 and a 1 year high of $12.32. The stock has a market cap of $4.69 million, a PE ratio of -0.29 and a beta of 0.16.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Evoke Pharma in a report on Wednesday, May 7th. They issued a “sell” rating for the company.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.